Halozyme Therapeutics (HALO) 7.57 $HALO
Robbins Arroyo LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders
PR Newswire - 34 mins ago
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) breached their fiduciary duties to shareholders. Halozyme is a biopharmaceutical company that researches, develops, and commercializes human enzymes that facilitate the delivery of injected drugs and fluids.
Coca-Cola and MasterCard are big market movers
AP - Tue Apr 15, 4:01PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
43.8% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Mon Apr 14, 10:59AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 1 month, Halozyme Therapeutics has returned 43.80% as of today's recent price of $7.66.
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 6:00AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company April 11 Weekly Loss voxeljet AG $15.10 40% World...
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme
PR Newswire - Wed Apr 09, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. According to the FDA, this action was being taken in view of the company's recent decision to temporarily halt enrollment and dosing of PEGPH20 in the Phase 2 trial.
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 08, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Halozyme Falls on Phase II Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 11:10AM CDT
Halozyme's shares fell after the company announced its decision to temporarily halt patient enrollment and dosing of PEGPH20 in phase II study.
The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ...
Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting
PR Newswire - Tue Apr 08, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the American Association for Cancer Research (AACR) annual meeting being held in San Diego. The first presentation includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes preclinical data showing that overproduction of hyaluronan (HA) in tumor stroma enhances tumor growth, and that PEGPH20, as a single agent, suppresses growth of HA-rich tumors and inhibits early events of epithelial to mesenchymal transition (EMT), a key process involved in metastasis. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme, which degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
Downtrend Call Working As Halozyme Therapeutics Stock Falls 38.1% (HALO)
Comtex SmarTrend(R) - Mon Apr 07, 9:39AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 4 weeks, Halozyme Therapeutics has returned 38.08% as of today's recent price of $8.44.
Data Review on Active Stocks -- Research on Procter & Gamble, Halozyme Therapeutics, Symantec, and IsoRay
PR Newswire - Mon Apr 07, 7:25AM CDT
The trading session on Friday, April 04, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,412.71, down 0.96% and the NASDAQ Composite closed at 4,127.73, down 2.60%. The S&P 500 finished the session 1.25% lower at 1,865.09. The losses were broad based as nine out of ten sectors posted losses. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include The Procter & Gamble Co. (NYSE: PG), Halozyme Therapeutics Inc. (NASDAQ: HALO), Symantec Corp. (NASDAQ: SYMC) and IsoRay Inc. (NYSE MKT: ISR). Free technical research on PG, HALO, SYMC and ISR can be downloaded upon signing up at:
IMS Health Holdings Makes a Strong Debut on the NYSE; Halozyme Therapeutics Temporarily Suspends Phase 2 PEGPH20 Trials
ACCESSWIRE - Sun Apr 06, 11:16PM CDT
IMS Health Holdings, Inc. (NYSE: IMS) - For an in-depth report on IMS Health Holdings, Inc. Corporation follow: www.BullTrends.com/stockquote/IMS
After a 27% Plunge, Is Halozyme a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Apr 06, 11:00AM CDT
Halozyme Therapeutics, Inc.'s stock plummeted by 27% on Friday after management reported that it had halted enrollment and dosing in its phase 2 pancreatic cancer trial of PEGPH20 as a "precautionary measure." The trial was halted at the request of...
This Week in Biotech: Data Disappointments Come in Threes
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 05, 1:15PM CDT
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 05, 7:10AM CDT
Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them....
Robbins Arroyo LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders
PR Newswire - 34 mins ago
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) breached their fiduciary duties to shareholders. Halozyme is a biopharmaceutical company that researches, develops, and commercializes human enzymes that facilitate the delivery of injected drugs and fluids.
Coca-Cola and MasterCard are big market movers
AP - Tue Apr 15, 4:01PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
43.8% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Mon Apr 14, 10:59AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 1 month, Halozyme Therapeutics has returned 43.80% as of today's recent price of $7.66.
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 13, 6:00AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company April 11 Weekly Loss voxeljet AG $15.10 40% World...
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme
PR Newswire - Wed Apr 09, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. According to the FDA, this action was being taken in view of the company's recent decision to temporarily halt enrollment and dosing of PEGPH20 in the Phase 2 trial.
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 08, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
Halozyme Falls on Phase II Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 11:10AM CDT
Halozyme's shares fell after the company announced its decision to temporarily halt patient enrollment and dosing of PEGPH20 in phase II study.
The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ...
Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting
PR Newswire - Tue Apr 08, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the American Association for Cancer Research (AACR) annual meeting being held in San Diego. The first presentation includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes preclinical data showing that overproduction of hyaluronan (HA) in tumor stroma enhances tumor growth, and that PEGPH20, as a single agent, suppresses growth of HA-rich tumors and inhibits early events of epithelial to mesenchymal transition (EMT), a key process involved in metastasis. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme, which degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
Downtrend Call Working As Halozyme Therapeutics Stock Falls 38.1% (HALO)
Comtex SmarTrend(R) - Mon Apr 07, 9:39AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 4 weeks, Halozyme Therapeutics has returned 38.08% as of today's recent price of $8.44.
Data Review on Active Stocks -- Research on Procter & Gamble, Halozyme Therapeutics, Symantec, and IsoRay
PR Newswire - Mon Apr 07, 7:25AM CDT
The trading session on Friday, April 04, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,412.71, down 0.96% and the NASDAQ Composite closed at 4,127.73, down 2.60%. The S&P 500 finished the session 1.25% lower at 1,865.09. The losses were broad based as nine out of ten sectors posted losses. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include The Procter & Gamble Co. (NYSE: PG), Halozyme Therapeutics Inc. (NASDAQ: HALO), Symantec Corp. (NASDAQ: SYMC) and IsoRay Inc. (NYSE MKT: ISR). Free technical research on PG, HALO, SYMC and ISR can be downloaded upon signing up at:
IMS Health Holdings Makes a Strong Debut on the NYSE; Halozyme Therapeutics Temporarily Suspends Phase 2 PEGPH20 Trials
ACCESSWIRE - Sun Apr 06, 11:16PM CDT
IMS Health Holdings, Inc. (NYSE: IMS) - For an in-depth report on IMS Health Holdings, Inc. Corporation follow: www.BullTrends.com/stockquote/IMS
After a 27% Plunge, Is Halozyme a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Apr 06, 11:00AM CDT
Halozyme Therapeutics, Inc.'s stock plummeted by 27% on Friday after management reported that it had halted enrollment and dosing in its phase 2 pancreatic cancer trial of PEGPH20 as a "precautionary measure." The trial was halted at the request of...
This Week in Biotech: Data Disappointments Come in Threes
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 05, 1:15PM CDT
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 05, 7:10AM CDT
Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them....
